Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00059475
What this trial is testing

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Who this might be right for
Melanoma
National Cancer Institute (NCI) 138
Not applicableLooking for participantsNCT07680452
What this trial is testing

Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition

Who this might be right for
Melanoma (Skin Cancer)
Charite University, Berlin, Germany 60
Testing effectiveness (Phase 2)Ended earlyNCT00704938
What this trial is testing

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Who this might be right for
Kidney CancerMelanoma (Skin)Unspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC) 3
Testing effectiveness (Phase 2)UnknownNCT03528408
What this trial is testing

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Who this might be right for
MelanomaOcular Melanoma
Suthee Rapisuwon 52
Testing effectiveness (Phase 2)Study completedNCT01251978
What this trial is testing

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Who this might be right for
Choroidal Melanoma
New England Retina Associates 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT01416831
What this trial is testing

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Who this might be right for
Metastatic Melanoma
Providence Health & Services 44
Testing effectiveness (Phase 2)Looking for participantsNCT05512481
What this trial is testing

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Who this might be right for
MelanomaAcral MelanomaTemozolomide+4 more
Peking University Cancer Hospital & Institute 60
Testing effectiveness (Phase 2)Ended earlyNCT00929019
What this trial is testing

Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Who this might be right for
Uveal Melanoma
Radboud University Medical Center 23
Testing effectiveness (Phase 2)Study completedNCT00003091
What this trial is testing

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Who this might be right for
Kidney CancerMelanoma (Skin)
Hoag Memorial Hospital Presbyterian 40
Not applicableStudy completedNCT00617799
What this trial is testing

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

Who this might be right for
Kidney CancerMelanoma (Skin)
University of Nebraska 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04722575
What this trial is testing

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Who this might be right for
Melanoma
Fondazione Melanoma Onlus 95
Testing effectiveness (Phase 2)Study completedNCT01740557
What this trial is testing

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Who this might be right for
Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
M.D. Anderson Cancer Center 10
Early research (Phase 1)Study completedNCT00002854
What this trial is testing

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
City of Hope Medical Center 33
Early research (Phase 1)Active Not RecruitingNCT03589339
What this trial is testing

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Who this might be right for
RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant Tumour+8 more
Nanobiotix 145
Testing effectiveness (Phase 2)Looking for participantsNCT06365619
What this trial is testing

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Who this might be right for
Melanoma
University of Utah 25
Testing effectiveness (Phase 2)Ended earlyNCT03277352
What this trial is testing

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Who this might be right for
Advanced MalignanciesMetastatic Cancer
Incyte Biosciences International Sàrl 10
Not applicableStudy completedNCT02150369
What this trial is testing

Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms

Who this might be right for
Metastatic Renal Cell CarcinomaMetastatic MelanomaHigh-dose Interleukin-2
Duke University 32
Testing effectiveness (Phase 2)Study completedNCT01708941
What this trial is testing

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Who this might be right for
Recurrent MelanomaStage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7+2 more
National Cancer Institute (NCI) 88
Large-scale testing (Phase 3)Study completedNCT01682083
What this trial is testing

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

Who this might be right for
Melanoma
Novartis Pharmaceuticals 870
Early research (Phase 1)Study completedNCT00418496
What this trial is testing

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Who this might be right for
Renal CancerMelanoma
Ohio State University Comprehensive Cancer Center 17
Next Page